Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus MMF in childhood-onset idiopathic nephrotic syndrome
2023-505140-19-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial in Idiopathic nephrotic syndrome (INS) and nephrosis comparing Obinutuzumab with Mycophenolate mofetil (2 arms). Primary endpoint: Percentage of participants with sustained complete remission at 1 year. Started Jul 2023; status: completed.
02
Drugs
obinutuzumabmycophenolate mofetil
03
Conditions
Idiopathic nephrotic syndrome (INS)nephrosis
Beyond the preview
Go deeper on 2023-505140-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505140-19-00.